BFM
AVDL

Boothbay Fund Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Boothbay Fund Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-123,200
Closed -$841K – 2243
2022
Q1 		$841K Buy
+123,200
New +$847K 0.02% 1008
2020
Q2 		– Sell
-831
Closed -$660K – 962
2020
Q1 		$660K Buy
+831
New +$6.38K 0.05% 401

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Boothbay Fund Management's AVDL Position: Q2 2022 in Review

Boothbay Fund Management sold out of Avadel Pharmaceuticals (AVDL) in Q2 2022, closing a stake of 61,600 shares — an estimated $421K sold.

Boothbay Fund Management first reported a position in AVDL in Q3 2015 and held it in 5 quarters. The position peaked at $421K in Q1 2022. 82 funds tracked by Wall St. Rank hold AVDL as of Q2 2022.

  • Boothbay Fund Management reported no remaining Avadel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 61,600 Avadel Pharmaceuticals shares in Q2 2022, an estimated $421K.
  • Boothbay Fund Management first reported a position in Avadel Pharmaceuticals in Q3 2015 and held it in 5 quarters.
  • Boothbay Fund Management's Avadel Pharmaceuticals position peaked at $421K in Q1 2022.
  • 82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.